Rhenman & Partners Asset Management’s 10x Genomics TXG Stock Holding History

Rhenman & Partners Asset Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-68,000	Closed	-$2.81M	–	94
2023 Q3	$2.81M	Sell	68,000 -68,000	-50%	-$3.54M	0.3%	66
2023 Q2	$7.59M	Sell	136,000 -14,000	-9%	-$758K	0.8%	40
2023 Q1	$7.81M	Buy	150,000 +75,000	+100%	+$3.5M	0.86%	38
2022 Q4	$2.73M	Hold	75,000	–	–	0.29%	75
2022 Q3	$2.04M	Buy	+75,000	New	+$2.86M	0.21%	85

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Rhenman & Partners Asset Management's TXG Position: Q4 2023 in Review

Rhenman & Partners Asset Management sold out of 10x Genomics (TXG) in Q4 2023, closing a stake of 68,000 shares — an estimated $2.81M sold.

Rhenman & Partners Asset Management first reported a position in TXG in Q3 2022 and held it in 5 quarters. The position peaked at $7.81M in Q1 2023. 275 funds tracked by Wall St. Rank hold TXG as of Q4 2023.

Rhenman & Partners Asset Management reported no remaining 10x Genomics position as of Q4 2023 after selling out during the quarter.
Rhenman & Partners Asset Management sold 68,000 10x Genomics shares in Q4 2023, an estimated $2.81M.
Rhenman & Partners Asset Management first reported a position in 10x Genomics in Q3 2022 and held it in 5 quarters.
Rhenman & Partners Asset Management's 10x Genomics position peaked at $7.81M in Q1 2023.
275 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2023.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.